A clinical trial of adjunctive oestrogen treatment in women with schizophrenia

被引：49
作者：
Kulkarni J. [1 ,4 ]
Riedel A. [1 ]
De Castella A.R. [1 ]
Fitzgerald P.B. [1 ]
Rolfe T.J. [1 ]
Taffe J. [2 ]
Burger H. [3 ]
机构：
[1] Dandenong Psychiat. Research Centre, Monash University, Dept. of Psychological Medicine, Melbourne, Vic.
[2] School of Mathematical Sciences, Swinburne University, Melbourne, Vic.
[3] Prince Henry's Inst. of Med. Res., Monash Medical Centre, Clayton, Vic.
[4] Alfred Psychiatry Research Centre, Alfred Hospital, Prahran, Vic. 3181, Commercial Road
来源：
Archives of Women's Mental Health | 2002年 / 5卷 / 3期
关键词：
Dopamine; Oestrogen/estrogen; Prolactin; Schizophrenia; Serotonin;
D O I：
10.1007/s00737-002-0001-5
中图分类号：
学科分类号：
摘要：
A double-blind, 28-day, placebo-controlled study was conducted with three groups of women of child-bearing age (N = 12 in each group) who received standardised antipsychotic medication plus a) 50 μg transdermal estradiol or b) 100 μg transdermal estradiol or c) transdermal placebo. Preliminary analyses show that women receiving 100 μg of estradiol made greater improvements in the symptoms of schizophrenia than either the 50 μg estradiol or placebo groups. The addition of 100 μg adjunctive transdermal oestrogen significantly enhanced treatment responsivity of acute, severe psychotic symptoms in women with schizophrenia. The positive impact of oestrogen treatment on psychotic symptoms via a multiplicity of possible actions (see accompanying articles in this issue) may prove clinically useful in the overall treatment of women with schizophrenia.
引用
收藏
页码：99 / 104
页数：5
相关论文
共 17 条
  • [1] Di Paolo T., Modulation of brain dopamine transmission by sex steroids, Rev Neurosci, 5, pp. 27-41, (1994)
  • [2] Di Paolo T., Poyet P., Labrie F., Effect of chronic estradiol and haloperidol treatment on striatal dopamine receptors, Eur J Pharmacol, 73, pp. 105-106, (1981)
  • [3] Di Paolo T., Poyet P., Labrie F., Effect of prolactin and estradiol on rat striatal dopamine receptors, Life Sci, 31, pp. 2921-2929, (1982)
  • [4] Grunder G., Wetzel H., Schlosser R., Anghelescu I., Hillert A., Lange K., Hiemke C., Benkert O., Neuroendocrine response to antipsychotics: Effects of drug type and gender, Biol Psychiatry, 45, pp. 89-97, (1999)
  • [5] Hafner H., Behrens S., De Vry J., Gattaz W.F., An animal model for the effects of estradiol on dopamine-mediated behavior: Implications for sex differences in schizophrenia, Psychiatry Res, 38, pp. 125-134, (1991)
  • [6] Kay S.R., Fiszbein A., Opler L.A., The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, 13, pp. 261-276, (1987)
  • [7] Kulkarni J., DeCastella A., Thompson K., Assessment of menstrual cycle phase in women, Biennial Winter Workshop on Schizophrenia, (1994)
  • [8] Kulkarni J., De Castella A., Smith D., Taffe J., Keks N., Copolov D., A clinical trial of the effects of estrogen in acutely psychotic women, Schizophr Res, 20, pp. 247-252, (1996)
  • [9] Kulkarni J., DeCastella A., Taffe J., Clinical adjunctive estrogen trial in men with schizophrenia: A pilot study, Schizophr Res, 36, (1999)
  • [10] Kulkarni J., Reidel A., De Castella A., Fitzgerald P., Rolfe T., Taffe J., Burger H., Estrogen - A potential treatment for schizophrenia, Schizophr Res, 48, pp. 137-144, (2001)
12